Which regimens does NCCN consider useful in select circumstances of multiple myeloma (MM)?

Updated: Mar 06, 2020
  • Author: Dhaval Shah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

The NCCN considers the following regimens useful in certain circumstances (although triplet regimens should be used as the standard, patients not considered candidates for a 3-drug regimen can be started on a 2-drug regimen, with the third drug added once performance status improves):

  • Bortezomib/doxorubicin/dexamethasone
  • Carfilzomib/cyclophosphamide/dexamethasone
  • Ixazomib/cyclophosphide/dexamethasone
  • Bortezomib/thalidomide/dexamethasone (category 1)
  • Cyclophosphamide/lenalidomide/dexamethasone
  • Dexamethasone/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide/bortezomib (VTD-PACE)

Patients should be assessed for response after two cycles of one of the above regimens.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!